Premium
Clinical and serologic effects of live attenuated serum inhibitor‐resistant influenza B vaccine in seronegative adults
Author(s) -
Miller Louis W.,
Togo Yasushi,
Hornick Richard B.
Publication year - 1977
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890010306
Subject(s) - virology , antibody , serology , immunology , medicine , hemagglutination assay , titer , viral shedding , virus , placebo , influenza a virus , alternative medicine , pathology
The clinical effects, nasal and serum antibody responses, and virus excretion of a live attenuated serum inhibitor‐resistant influenza B virus vaccine, R75, was evaluated in 43 seronegative healthy adults by a random double‐blind study. Symptom responses were minimal and were not significantly different between vaccine and placebo groups. No fevers, abnormalities in physical examination or laboratory testing developed during 4 weeks of observation. Among vaccinees, 10 (48%) developed serum hemagglutination‐inhibition (HI) antibodies, 16 (76%) developed serum neutralization (N) antibodies and 4(19%) developed nasal N antibodies. The GMT responses from study day 0 to day 28 were 4.0 to 10.4 for serum HI, 1.8 to 9.8 for serum N, and 1.0 to 1.4 for nasal N. There were no significant titer changes in the placebo group. No virus excretion was detected. Although there are some questions concerning the relationship of antibody levels to protection, the low antibody responses in this study are an indication that R75 is not sufficiently immunogenic.